Abstract
Objective The purpose of this study was to explore the molecular mechanism of Danggui Buxue Decoction (DBD) intervening premature ovarian failure (POF). Methods The active compounds-targets network, active compounds-POF-targets network, and protein-protein interaction (PPI) network were constructed by a network pharmacology approach: Gene Ontology (GO) function and Kyoto Encyclopedia of Gene and Genome (KEGG) pathway analysis by DAVID 6.8 database. The molecular docking method was used to verify the interaction between core components of DBD and targets. Then, High-Performance Liquid Chromatography (HPLC) analysis was used to determine whether the DBD contained two key components including quercetin and kaempferol. Finally, the estrous cycle, organ index, ELISA, and western blot were used to verify that mechanism of DBD improved POF induced by cyclophosphamide (CTX) in rats. Results Based on the network database including TCMSP, Swiss Target Prediction, DisGeNET, DrugBank, OMIM, and Malacard, we built the active compounds-targets network and active compounds-POF-targets network. We found that 2 core compounds (quercetin and kaempferol) and 5 critical targets (TP53, IL6, ESR1, AKT1, and AR) play an important role in the treatment of POF with DBD. The GO and KEGG enrichment analysis showed that the common targets involved a variety of signaling pathways, including the reactive oxygen species metabolic process, release of Cytochrome C from mitochondria and apoptotic signaling pathway, p53 signaling pathway, the PI3K-Akt signaling pathway, and the estrogen signaling pathway. The molecular docking showed that quercetin, kaempferol, and 5 critical targets had good results regarding the binding energy. Chromatography showed that DBD contained quercetin and kaempferol compounds, which was consistent with the database prediction results. Based on the above results, we found that the process of DBD interfering POF is closely related to the balance of ESR and AR in TP53-AKT signaling pathway and verified animal experiments. In animal experiments, we have shown that DBD and its active compounds can effectively improve estrus cycle of POF rats, inhibit serum levels of FSH and LH, protein expression levels of Cytochrome C, BAX, p53, and IL6, and promote ovary index, uterine index, serum levels of E2 and AMH, and protein expression levels of AKT1, ESR1, AR, and BCL2. Conclusions DBD and its active components could treat POF by regulating the balance of ESR and AR in TP53-AKT signaling pathway.
Highlights
Premature ovarian failure (POF) is a disorder of the female reproductive system under the age of 40 years due to reduced ovarian function for various reasons
Active Compounds and Targets of Danggui Buxue Decoction (DBD). 22 active compounds in DBD were selected from the TCMSP database according to oral bioavailability (OB) ≥ 30% and DL ≥ 0.18
After comparing with the PubChem database, MOL000398-isoflavanone was deleted because it does not have matching compounds and Canonical SMILES sequences of the remaining 21 active compounds were obtained. e target compounds in DBD were searched from TCMSP and Swiss Target Prediction databases where 183 and 155 corresponding targets were obtained, respectively, after identifying their names in combination with Uniprot database. 312 targets remained after deleting duplicates
Summary
Premature ovarian failure (POF) is a disorder of the female reproductive system under the age of 40 years due to reduced ovarian function for various reasons. Evidence-Based Complementary and Alternative Medicine hormone (LH) to predict reproductive potential [2]. Hormone replacement therapy (HRT) is mainly used for the treatment of POF. Long-term treatment may cause anxiety, depression, irritability, and other adverse reactions. It may even induce certain complications such as endometrial cancer, breast cancer, and unexplained vaginal bleeding [4]. What is noteworthy is that the traditional Chinese medicine (TCM) as complementary medicine therapy has achieved extremely effective results, and greatly reduced the incidence of adverse reactions and complications [5]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Evidence-Based Complementary and Alternative Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.